Svetlana Bozinovski
Overview
Explore the profile of Svetlana Bozinovski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillman A, Bourgeat P, Cox T, Villemagne V, Fripp J, Huang K, et al.
J Alzheimers Dis
. 2025 Jan;
103(4):1257-1268.
PMID: 39865687
Background: The introduction of therapeutics for Alzheimer's disease has led to increased interest in precisely quantifying amyloid-β (Aβ) burden for diagnosis, treatment monitoring, and further clinical research. Recent positron emission...
2.
Krishnadas N, Dore V, Laws S, Porter T, Lamb F, Bozinovski S, et al.
Alzheimers Dement (Amst)
. 2022 Sep;
14(1):e12326.
PMID: 36051174
Introduction: Neocortical 3R4R (3-repeat/4-repeat) tau aggregates are rarely observed in the absence of amyloid beta (Aβ). F-MK6240 binds specifically to the 3R4R form of tau that is characteristic of Alzheimer's...
3.
Krishnadas N, Huang K, Schultz S, Dore V, Bourgeat P, Goh A, et al.
J Alzheimers Dis
. 2022 Jul;
88(4):1627-1637.
PMID: 35811517
Background: In Alzheimer's disease, heterogeneity has been observed in the postmortem distribution of tau neurofibrillary tangles. Visualizing the topography of tau in vivo may facilitate clinical trials and clinical practice....
4.
Villemagne V, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, et al.
J Nucl Med
. 2022 Jan;
63(10):1551-1559.
PMID: 35086898
Reactive gliosis, characterized by reactive astrocytes and activated microglia, contributes greatly to neurodegeneration throughout the course of Alzheimer disease (AD). Reactive astrocytes overexpress monoamine oxidase B (MAO-B). We characterized the...
5.
Villemagne V, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, et al.
J Nucl Med
. 2022 Jan;
63(10):1560-1569.
PMID: 35086892
A neuroinflammatory reaction in Alzheimer disease (AD) brains involves reactive astrocytes that overexpress monoamine oxidase-B (MAO-B). F-()-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline (F-SMBT-1) is a novel F PET tracer highly selective for MAO-B. We characterized...
6.
Rowe C, Krishnadas N, Ackermann U, Dore V, Goh R, Guzman R, et al.
Psychiatry Res Neuroimaging
. 2021 Aug;
316:111354.
PMID: 34399286
M1 and M4 muscarinic receptor (mAChR) agonists are under development for the treatment of schizophrenia, Alzheimer's and Parkinson's disease. We performed first-in-human PET imaging of mAChR with F-Fluorobenzyl-Dexetimide (FDEX) in...
7.
van der Kall L, Truong T, Burnham S, Dore V, Mulligan R, Bozinovski S, et al.
Neurology
. 2020 Nov;
96(5):e662-e670.
PMID: 33184233
Objective: To determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. Methods:...
8.
Xu S, Alexander P, Lie Y, Dore V, Bozinovski S, Mulligan R, et al.
BMJ Open
. 2018 Nov;
8(11):e025533.
PMID: 30446576
Objectives: To further validate the diagnostic utility of F-AV-133 vesicular monoamine transporter type 2 (VMAT2) positron emission tomography (PET) in patients with clinically uncertain parkinsonian syndromes (CUPS) by comparison to...